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There was no plan
to compare PCI
and CABG. . .
Almost all of the
CABG was done in
2- and 3-vessel
patients; however,
about 40% of the
PCI was done in
1-vessel patients.
The patients
treated with PCI
had less ischemia,
a lesser extent of
coronary artery
disease, a better
prognosis, and a
decreased opportu-
nity to improve
that prognosis with
intervention.
Additional analyses
of BARI 2D will
expand our knowl-
edge on how best to
manage revascular-
ization.DITOR’S PAGE
ARI 2D: Headlines Are Not Enough
hose of us involved in the performance and interpretation of BARI 2D (Bypass
ngioplasty Revascularization Investigation Type 2 Diabetes) have been trying to explain
he findings to patients and the public. It is a difficult job which involves a lot of nuance
nd is not suited to 1-line conclusions. I will try to give my observations of what we
howed because I think some remain confused. Even the National Institute of Health
ebsite headlines falls into the word-conserving trap of trying to simplify the message:
Optimal Medical Therapy As Beneficial As Elective Revascularization Procedures in
atients with Type 2 Diabetes and Stable Coronary Heart Disease” (1). What was the
rial setting out to show (2)? I will not discuss the insulin-providing versus the insulin-
ensitizing arm of the study, but the revascularization versus continued medical therapy
rm. The question here was: Among patients with diabetes and ischemic heart disease
ith clinical and anatomic presentations that allowed equipoise between routine
evascularization or no routine revascularization, will the early revascularization be
ssociated with improved clinical outcomes? There was no plan to compare percutaneous
oronary intervention (PCI) and coronary artery bypass grafting (CABG) but to select the
revascularization strategies at the discretion of the investigators. Guidance was given to
he investigative sites to consider the results of the BARI trial and others that showed
etter outcomes in diabetic patients with surgery for more complex multivessel disease and
o use PCI for less extensive disease. The greater extent of disease in the CABG stratum
as reflected by the 5-year mortality for patients randomized to medical therapy (16.4%)
ompared with the PCI stratum patients randomized to medical therapy (10.2%). Almost
ll of the CABG was done in 2- and 3-vessel patients; however, about 40% of the PCI
as done in 1-vessel patients. This study of the strategy of revascularization with the tool
he experienced investigators felt best for their patients at their sites was perfectly
easonable. The result was that the strategy of routine revascularization did not result in
n improved 5-year outcome compared with a deferred strategy of performing intervention
n the medical group only if needed for future symptoms or ischemia. Of the medically
reated patients, 40% did receive this deferred revascularization during follow-up.
The comparison of the tools used to achieve this revascularization result is inappropriate.
ither PCI or CABG was chosen to perform the revascularization in very different patients.
nalysis of the patients who ended up in the surgical group showed that they were
ignificantly more ischemic and had more extensive coronary artery disease. These are patients
ell-known to have adverse outcomes and to have benefit from relief of that ischemia. The
atients treated with PCI had less ischemia, a lesser extent of coronary artery disease, a better
rognosis, and a decreased opportunity to improve that prognosis with intervention. It is
onceivable that patients who had improvement with revascularization may have benefited
isproportionately by having CABG rather than PCI, and it is conceivable that those with less
isease may have been more safely and effectively treated with PCI than undergoing CABG,
ut neither of these questions were studied in BARI 2D.
In talking to patients I try to help them understand the gradation of risk that exists
mong patients with various extents of coronary artery disease and ischemia and the
oncept that relief of extensive ischemia is of greater benefit than lesser degrees of
schemia relief. This approach should allow many patients similar to those in the trial to
ontinue aggressive medical therapy without incurring increased risk compared with
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810outine revascularization. There are, however, many
iabetic patients who can benefit significantly from relief
f major ischemia, most of whom were not similar to the
ARI 2D patients; in such patients revascularization
the best procedure at each local institution, i.e.,
ABG, PCI, or hybrid procedures) should not be
nappropriately denied. Some have confused the patient
election in BARI 2D with that in the ongoing
REEDOM (Future REvascularization Evaluation in
atients with Diabetes mellitus: Optimal management
f Multivessel disease) trial, which is limited to patients
udged to be requiring revascularization. BARI 2D would
y definition exclude such patients. Additional analyses of
ARI 2D will expand our knowledge on how best to
anage revascularization. It was a very well done trial
hat helps aim us in the right direction—but, it is not so
ell suited for a single headline.ddress for correspondence to:
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